{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:42:53Z","timestamp":1779918173506,"version":"3.53.1"},"reference-count":59,"publisher":"Becaris Publishing Limited","issue":"2","funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            This study estimates the societal benefits of using biologics like secukinumab (SEC) instead of nonsteroidal anti-inflammatory drugs\u00a0for treating patients with ankylosing spondylitis in Germany.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A Markov and a population model were used to predict the functional impairment of German ankylosing spondylitis patients using SEC or nonsteroidal anti-inflammatory drugs. This was translated into avoided productivity losses, which were valued according to gross value added.\n            <jats:bold>Results:<\/jats:bold>\n            The productivity impairment of SEC users was predicted to decrease by 20 percentage points, corresponding to 12.8 and 32.7\u00a0million hours in paid and unpaid work and a monetary value of \u20ac1.6\u00a0billion from 2016 to 2030. Accounting for economic spillover effects increases the societal value to \u20ac 3.3\u00a0billion.\n            <jats:bold>Conclusion:<\/jats:bold>\n            The improvements in functional impairment due to biologics could lead to sizable productivity effects.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0077","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:41:13Z","timestamp":1606747273000},"page":"143-155","source":"Crossref","is-referenced-by-count":5,"title":["The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab"],"prefix":"10.57264","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6565-5353","authenticated-orcid":false,"given":"Sebastian","family":"Himmler","sequence":"first","affiliation":[{"name":"WifOR Institute, Darmstadt 64283, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C","family":"Branner","sequence":"additional","affiliation":[{"name":"WifOR Institute, Darmstadt 64283, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A","family":"Ostwald","sequence":"additional","affiliation":[{"name":"WifOR Institute, Darmstadt 64283, Germany"},{"name":"School of International Business &amp; Entrepreneurship (SIBE) Steinbeis University, Herrenberg 71083, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_5_3_2","volume-title":"Harrison's Rheumatology.","author":"Taurog J","year":"2006","unstructured":"Taurog J. The Spondyloarthritides. In: Harrison's Rheumatology. 16th Ed. McGraw-Hill, Fauci A, Langford C (Eds). NY, USA (2006).","edition":"16"},{"issue":"9570","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet 369(9570), 1379\u20131390 (2007).","journal-title":"Lancet"},{"issue":"7","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","article-title":"Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes","volume":"66","author":"Baraliakos X","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann. Rheum. Dis. 66(7), 910\u2013915 (2007).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort","volume":"60","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort. Arthritis Rheum. 60(3), 717\u2013727 (2009).","journal-title":"Arthritis Rheum."},{"issue":"11","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3899\/jrheum.130542","article-title":"Juvenile versus adult-onset ankylosing spondylitis -- clinical, radiographic, and social outcomes. a systematic review","volume":"40","author":"Jadon DR","year":"2013","unstructured":"Jadon DR, Ramanan AV, Sengupta R. Juvenile versus adult-onset ankylosing spondylitis -- clinical, radiographic, and social outcomes. a systematic review. J. Rheumatol. 40(11), 1797\u20131805 (2013).","journal-title":"J. Rheumatol."},{"issue":"1","key":"e_1_3_5_8_2","first-page":"49","article-title":"Clinical evaluation of ankylosing spondylitis in Switzerland","volume":"5","author":"Brunner R","year":"2002","unstructured":"Brunner R, Kissling RO, Auckenthaler C, Fortin J. Clinical evaluation of ankylosing spondylitis in Switzerland. Pain Physician 5(1), 49\u201356 (2002).","journal-title":"Pain Physician"},{"issue":"4","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology 53(4), 650\u2013657 (2014).","journal-title":"Rheumatology"},{"key":"e_1_3_5_10_2","unstructured":"G-BA. Dossier Zur Nutzenbewertung Gem\u00e4\u00df \u00a7 35a SGB V. Secukinumab (Cosentyx). Modul 3C. Aktive AS. Berlin (2015). [cited 2019 Aug 1]. https:\/\/www.g-ba.de\/downloads\/92-975-1271\/2015-12-11_Modul3C_Secukinumab.pdf"},{"issue":"5","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/rheumatology\/keu398","article-title":"Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study","volume":"54","author":"Giacomelli R","year":"2015","unstructured":"Giacomelli R, Gorla R, Trotta F Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology 54(5), 792\u2013797 (2015).","journal-title":"Rheumatology"},{"issue":"6","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review","volume":"14","author":"Kotsis K","year":"2014","unstructured":"Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev. Pharmacoecon. Outcomes Res. 14(6), 857\u2013872 (2014).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"11","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","article-title":"Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis","volume":"38","author":"Kr\u00fcger K","year":"2018","unstructured":"Kr\u00fcger K, von Hin\u00fcber U, Meier F Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol. Int. 38(11), 2121\u20132131 (2018).","journal-title":"Rheumatol. Int."},{"issue":"9","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/ard.2005.046367","article-title":"Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany","volume":"65","author":"Huscher D","year":"2006","unstructured":"Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65(9), 1175\u20131183 (2006).","journal-title":"Ann. Rheum. Dis."},{"issue":"55","key":"e_1_3_5_15_2","first-page":"S112","article-title":"The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Boonen A","year":"2009","unstructured":"Boonen A, Mau W. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin. Exp. Rheumatol. 27(55 Suppl. 4), S112\u2013S117 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03009742.2010.487838","article-title":"Impact of ankylosing spondylitis on work in patients across the UK","volume":"40","author":"Healey E","year":"2011","unstructured":"Healey E, Haywood K, Jordan K, Garratt A, Packham J. Impact of ankylosing spondylitis on work in patients across the UK. Scand. J. Rheumatol. 40(1), 34\u201340 (2011).","journal-title":"Scand. J. Rheumatol."},{"issue":"2","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward MM","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 68(2), 282\u2013298 (2016).","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76(6), 978\u2013991 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_5_19_2","article-title":"TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis","author":"NICE","year":"2016","unstructured":"NICE. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Technology Appraisal Guidance [TA383]. (2016). [cited 2019 Apr 30]. https:\/\/www.nice.org.uk\/guidance\/ta383","journal-title":"Technology Appraisal Guidance [TA383]."},{"issue":"10","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14656566.2015.1052744","article-title":"Pharmacological therapy of spondyloarthritis","volume":"16","author":"Palazzi C","year":"2015","unstructured":"Palazzi C, D'Angelo S, Gilio M, Leccese P, Padula A, Olivieri I. Pharmacological therapy of spondyloarthritis. Expert Opin. Pharmacother. 16(10), 1495\u20131504 (2015).","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","article-title":"Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis","volume":"47","author":"Coates LC","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NWF Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 47(6), 897\u2013900 (2008).","journal-title":"Rheumatology"},{"key":"e_1_3_5_22_2","unstructured":"European Medicines Agency. Cosentyx: EPAR - product information. (2018). [cited 2019 Aug 1]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"issue":"1","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","article-title":"Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany","volume":"36","author":"Lyu R","year":"2016","unstructured":"Lyu R, Govoni M, Ding Q Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol. Int. 36(1), 143\u2013153 (2016).","journal-title":"Rheumatol. Int."},{"issue":"2","key":"e_1_3_5_24_2","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh JA","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011(2), CD008794 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of Secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a Phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar AA","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL Effect of Secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a Phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 68(12), 2901\u20132910 (2016).","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper J","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann. Rheum. Dis. 76(3), 571\u2013592 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"26","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten D","year":"2015","unstructured":"Baeten D, Sieper J, Braun J Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373(26), 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_5_28_2","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase III MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2018","unstructured":"Baraliakos X, Kivitz AJ, Deodhar AA Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase III MEASURE 1 trial. Clin. Exp. Rheumatol. 36(1), 50\u201355 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the Phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega H","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the Phase III trial, MEASURE 2. RMD Open 3(2), e000592 (2017).","journal-title":"RMD Open"},{"issue":"8","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40273-018-0675-9","article-title":"Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK","volume":"36","author":"Emery P","year":"2018","unstructured":"Emery P, Van Keep M, Beard S Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics 36(8), 1015\u20131027 (2018).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_5_31_2","unstructured":"Novartis. Clinical study report- Week 52 analysis of Phase III trial CAIN457F2310. (2014). [Data on file]."},{"issue":"11","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland G","year":"2011","unstructured":"Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann. Rheum. Dis. 70(11), 1921\u20131925 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_5_33_2","unstructured":"Destatis. Allgemeine Sterbetafel 2010\/12. Statistisches Bundesamt Wiesbaden Germany (2015)."},{"issue":"1","key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00393-013-1205-y","article-title":"Trends der Erwerbst\u00e4tigkeit von Rheumakranken: Ergebnisse aus Sozialversicherungsdaten und Kerndokumentation der Rheumazentren in Deutschland","volume":"73","author":"Mau W","year":"2014","unstructured":"Mau W, Thiele K, Lamprecht J. Trends der Erwerbst\u00e4tigkeit von Rheumakranken: Ergebnisse aus Sozialversicherungsdaten und Kerndokumentation der Rheumazentren in Deutschland. Z. Rheumatol. 73(1), 11\u201319 (2014).","journal-title":"Z. Rheumatol."},{"key":"e_1_3_5_35_2","unstructured":"Destatis. Bev\u00f6lkerung Erwerbst\u00e4tige Erwerbslose: Deutschland Jahre Geschlecht Altersgruppen. Genesis-Online (Table 12211-0003). Statistisches Bundesamt Wiesbaden Germany (2019). https:\/\/www-genesis.destatis.de\/genesis\/online"},{"key":"e_1_3_5_36_2","unstructured":"Eurostat. Annual population by sex age degree of urbanisation and labour status (1 000). (2019). [cited 2019 Apr 12]. https:\/\/appsso.eurostat.ec.europa.eu\/nui\/show.do?dataset=lfsa_pgauws&lang=en"},{"issue":"8","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson JJ","year":"2001","unstructured":"Anderson JJ, Baron G, Van Der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 44(8), 1876\u20131886 (2001).","journal-title":"Arthritis Rheum."},{"issue":"12","key":"e_1_3_5_38_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21(12), 2286\u20132291 (1994).","journal-title":"J. Rheumatol."},{"issue":"1","key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-016-1162-3","article-title":"Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort","volume":"18","author":"de Hooge M","year":"2016","unstructured":"de Hooge M, Ramonda R, Lorenzin M Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res. Ther. 18(1), 265 (2016).","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly MC","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5), 353\u2013365 (1993).","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40273-014-0209-z","article-title":"Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence","volume":"33","author":"Tang K","year":"2015","unstructured":"Tang K. Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. Pharmacoeconomics 33(1), 31\u201348 (2015).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_5_42_2","volume-title":"Economics of Household Production.","author":"Reid M","year":"1935","unstructured":"Reid M. Economics of Household Production. John Wiley and Sons Incorporated, NY, USA (1935)."},{"key":"e_1_3_5_43_2","first-page":"50","article-title":"Einfluss nicht-marktlicher T\u00e4tigkeiten auf den materiellen Wohlstand und die Einkommensverteilung in Deutschland","author":"Hofmann S","year":"2015","unstructured":"Hofmann S. Einfluss nicht-marktlicher T\u00e4tigkeiten auf den materiellen Wohlstand und die Einkommensverteilung in Deutschland. Sozio\u00f6konomische Schriften 50, (2015). https:\/\/doi.org\/10.3726\/978-3-653-05475-0","journal-title":"Sozio\u00f6konomische Schriften"},{"key":"e_1_3_5_44_2","unstructured":"Institut f\u00fcr Arbeitsmarkt- und Berufsforschung (IAB). Sonderauswertung der IAB Arbeitszeitrechnung. Arbeitszeit und Arbeitsvolumen nach Geschlecht und Altersgruppen (Inland abgestimmt auf VGR-Eckwerte). Institut f\u00fcr Arbeitsmarkt- und Berufsforschung (IAB) N\u00fcrnberg Germany (2017)."},{"key":"e_1_3_5_45_2","unstructured":"Destatis. Volkswirtschaftliche Gesamtrechnungen Inlandsproduktberechnung detaillierte Jahresergebnisse 2016 Fachserie 18 Reihe 1.4. Statistisches Bundesamt Wiesbaden Germany (2017)."},{"key":"e_1_3_5_46_2","article-title":"Erwerbst\u00e4tige Bev\u00f6lkerung Nach Geschlecht, Alter (10-Er Jahresgruppen) Und Wirtschaftszweig Abschnitte. Kombinierte Registerausz\u00e4hlung Und Hochrechnung Aus Der Haushaltsstichprobe","author":"Statistische \u00c4mter des Bundes und der L\u00e4nder","year":"2014","unstructured":"Statistische \u00c4mter des Bundes und der L\u00e4nder. Erwerbst\u00e4tige Bev\u00f6lkerung Nach Geschlecht, Alter (10-Er Jahresgruppen) Und Wirtschaftszweig Abschnitte. Kombinierte Registerausz\u00e4hlung Und Hochrechnung Aus Der Haushaltsstichprobe. Zensus 2011. (2014).","journal-title":"Zensus 2011."},{"key":"e_1_3_5_47_2","unstructured":"Destatis. Zeitverwendungserhebung - Aktivit\u00e4ten in Stunden Und Minuten F\u00fcr Ausgew\u00e4hlte Personengruppen 2012\/13. Statistisches Bundesamt Wiesbaden Germany (2015)."},{"key":"e_1_3_5_48_2","volume-title":"Durchschnittliche Zeitverwendung von Personen je Tag nach Ausgew\u00e4hlten Aktivit\u00e4ten, Personenmerkmalen und Altersgruppen [Special Analysis Based on Data of the Time Use Survey 2012\/13.","author":"Destatis","year":"2017","unstructured":"Destatis. Sonderauswertung auf Basis von Daten der Zeitverwendungserhebung 2012\/13. Durchschnittliche Zeitverwendung von Personen je Tag nach Ausgew\u00e4hlten Aktivit\u00e4ten, Personenmerkmalen und Altersgruppen [Special Analysis Based on Data of the Time Use Survey 2012\/13. Statistisches Bundesamt, Wiesbaden, Germany (2017)."},{"key":"e_1_3_5_49_2","unstructured":"Destatis. Volkswirtschaftliche Gesamtrechnungen: Wichtige Zusammenh\u00e4nge Im \u00dcberblick. Statistisches Bundesamt Wiesbaden Germany (2017)."},{"key":"e_1_3_5_50_2","unstructured":"Destatis. Volkswirtschaftliche Gesamtrechnungen Input-Output-Rechnung 2014. Fachserie 18 Reihe 1.4 (revision 2014 as of August 2017). Statistisches Bundesamt Wiesbaden Germany (2018)."},{"issue":"1","key":"e_1_3_5_51_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan SD","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 17(1), 5\u201314 (2014).","journal-title":"Value Health."},{"key":"e_1_3_5_52_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.socscimed.2015.09.008","article-title":"Unpaid work in health economic evaluations","volume":"144","author":"Krol M","year":"2015","unstructured":"Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc. Sci. Med. 144, 127\u2013137 (2015).","journal-title":"Soc. Sci. Med."},{"issue":"2","key":"e_1_3_5_53_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/14737167.2015.1001370","article-title":"The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Malinowski KP","year":"2015","unstructured":"Malinowski KP, Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev. Pharmacoeconomics Outcomes Res. 15(2), 285\u2013300 (2015).","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."},{"issue":"6","key":"e_1_3_5_54_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/ard.2009.116764","article-title":"Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost","volume":"69","author":"Boonen A","year":"2010","unstructured":"Boonen A, Brinkhuizen T, Landew\u00e9 R, Van Der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann. Rheum. Dis. 69(6), 1123\u20131128 (2010).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_5_55_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-015-0044-x","article-title":"Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-\u03b1 antagonists in management of ankylosing spondylitis: a dynamic population modelling study","volume":"13","author":"Tran-Duy A","year":"2015","unstructured":"Tran-Duy A, Boonen A, Van de Laar MAFJ, Severens JL. Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-\u03b1 antagonists in management of ankylosing spondylitis: a dynamic population modelling study. Cost Eff. Resour. Alloc. 13(1), 1\u201312 (2015).","journal-title":"Cost Eff. Resour. Alloc."},{"issue":"4","key":"e_1_3_5_56_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14737167.2019.1644169","article-title":"A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany","volume":"20","author":"Himmler S","year":"2020","unstructured":"Himmler S, M\u00fcller M, Bintu S, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev. Pharmacoecon. Outcomes Res. 20(4), 369\u2013378 (2020).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"7","key":"e_1_3_5_57_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0126105","article-title":"The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data","volume":"10","author":"Cooksey R","year":"2015","unstructured":"Cooksey R, Husain MJ, Brophy S The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS ONE 10(7), 1\u201317 (2015).","journal-title":"PLoS ONE"},{"issue":"11","key":"e_1_3_5_58_2","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1007\/s00296-011-2189-z","article-title":"Assessment of quality of life and depression in spouses of patients with ankylosing spondylitis","volume":"32","author":"Uludag M","year":"2012","unstructured":"Uludag M, Unalan H, Tuzun S Assessment of quality of life and depression in spouses of patients with ankylosing spondylitis. Rheumatol. Int. 32(11), 3511\u20133516 (2012).","journal-title":"Rheumatol. Int."},{"issue":"4","key":"e_1_3_5_59_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/art.20528","article-title":"Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis","volume":"51","author":"Brouwer WBF","year":"2004","unstructured":"Brouwer WBF, van Exel NJA, van de Berg B, Dinant HJ, Koopmanschap MA, van den Bos GAM. Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken). 51(4), 570\u2013577 (2004).","journal-title":"Arthritis Care Res. (Hoboken)."},{"issue":"2","key":"e_1_3_5_60_2","first-page":"246","article-title":"Healthcare costs and productivity losses directly attributable to ankylosing spondylitis","volume":"30","author":"Rafia R","year":"2012","unstructured":"Rafia R, Ara R, Packham J, Haywood K, Healey E. Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Clin. Exp. Rheumatol. 30(2), 246\u2013253 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"11","key":"e_1_3_5_61_2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.socscimed.2012.07.012","article-title":"Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects","volume":"75","author":"Krol M","year":"2012","unstructured":"Krol M, Brouwer WBF, Severens JL, Kaper J, Evers Silvia MAA. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects. Soc. Sci. Med. 75(11), 1981\u20131988 (2012).","journal-title":"Soc. Sci. Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:42:06Z","timestamp":1679229726000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/cer-2020-0077"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0077","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}